2026 Q2 - tulosraportti
42 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 666 | - | - | ||
| 1 | - | - | ||
| 306 | - | - | ||
| 5 000 | - | - | ||
| 683 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sittenJust a small refresher while we wait for news! The way forward We can look forward to several important R&D milestones in the second half of 2026 and the first half of 2027. These include the establishment of circVec generation 5 - an even more powerful circVec design that has shown the potential to provide 200 times or more gene expression compared to conventional AAV - the first in vivo data from AAV-circVec gene therapy in a relevant disease model, as well as in vivo results from the collaboration with the major pharmaceutical company. These results will be crucial when we define our R&D priorities and select a lead therapeutic candidate to be advanced towards clinical trials. To ensure access to key translational expertise in this central phase of Circio's development, the board has been strengthened through the appointment of Dr. Dinah Sah and by Dr. Robert Burns transitioning from deputy board member to regular board member. Dr. Sah has extensive experience in early drug development within RNA therapeutics and AAV gene therapy, and boasts a very strong track record. In her roles at Voyager Therapeutics and Alnylam Pharmaceuticals, she has led several programs from early research through to clinical development. Candidate selection, dosing, and the design of the preclinical documentation package are areas where gene therapy programs often win or lose. It is precisely in these areas that her experience is particularly relevant. With the expanded board, we are now developing both the corporate strategy and the R&D strategy for the next three to five years. Circio's ambition for the coming period is clear: We will continue to build on and consolidate our leading position in circular RNA technology. We will do this based on a therapeutic candidate that can establish clinical proof of concept, while translating strong scientific results into revenue-generating partnerships. The strict resource management and efficient R&D model that we have developed through four years of limited resources will be continued. What changes are the pace and scope of what we can now attempt to achieve. Dr. Erik Digman Wiklund
·4 t sittenWill there be a stock exchange announcement in two hours...? 🧐
·8 t sittenESGCT 27.-30. October - what do we actually know about the Circio abstracts? Facts Circio has three abstracts at ESGCT in Hamburg: - One oral presentation - Two posters The oral is titled "circVec: A DNA Vector Platform Harnessing Intracellular Circular RNA Biogenesis for Next-Generation T Cell Therapies" and will be held Wednesday 28. October at 10:00 in the session on non-viral vectors / nanotechnology and RNA therapeutics. The two posters: - P0089: circVec Reduces AAV Vector Dose Through Durable and Potent Circular RNA Expression - P0604: AAV-circVec Enhances Cardiac Expression While Minimizing Dose and Cellular Stress Full abstract texts will be released according to Circio on 27. October. The next R&D update is according to the Q2 call announced for the second half of November. My thoughts The poster titles are very similar to what we saw at ASGCT in May. I therefore expect updated AAV data (dose, expression, and cellular stress), not a completely new track. The oral is the more exciting one. The title points towards T cell therapy, but says nothing concrete about in vivo, LNP or CAR. It could just as well be in vitro data in human T cells as early in vivo results. Circio has itself guided in vivo T cell delivery, and CAR expression and durability in human T cells, as milestones over the next 6-12 months. Therefore I do not take for granted that the heaviest data will come already now. What I will look for - Is the expression shown in actual T cells (CD3/CD4/CD8), or just as total signal in spleen? - Is it CAR, or just reporter gene? - How long does it last, and what happens when the cells divide? - Is it compared against a strong control, or just own mVec? In short: Interesting program, but I am keeping my expectations in check until the abstracts are actually out.
·8 t sittenWould think that HOLD is the thing right now. And hence low turnover and few shares moving between hands among others. Only the daytraders tricking some bucks between themselves those who do not hold💥
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
42 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenJust a small refresher while we wait for news! The way forward We can look forward to several important R&D milestones in the second half of 2026 and the first half of 2027. These include the establishment of circVec generation 5 - an even more powerful circVec design that has shown the potential to provide 200 times or more gene expression compared to conventional AAV - the first in vivo data from AAV-circVec gene therapy in a relevant disease model, as well as in vivo results from the collaboration with the major pharmaceutical company. These results will be crucial when we define our R&D priorities and select a lead therapeutic candidate to be advanced towards clinical trials. To ensure access to key translational expertise in this central phase of Circio's development, the board has been strengthened through the appointment of Dr. Dinah Sah and by Dr. Robert Burns transitioning from deputy board member to regular board member. Dr. Sah has extensive experience in early drug development within RNA therapeutics and AAV gene therapy, and boasts a very strong track record. In her roles at Voyager Therapeutics and Alnylam Pharmaceuticals, she has led several programs from early research through to clinical development. Candidate selection, dosing, and the design of the preclinical documentation package are areas where gene therapy programs often win or lose. It is precisely in these areas that her experience is particularly relevant. With the expanded board, we are now developing both the corporate strategy and the R&D strategy for the next three to five years. Circio's ambition for the coming period is clear: We will continue to build on and consolidate our leading position in circular RNA technology. We will do this based on a therapeutic candidate that can establish clinical proof of concept, while translating strong scientific results into revenue-generating partnerships. The strict resource management and efficient R&D model that we have developed through four years of limited resources will be continued. What changes are the pace and scope of what we can now attempt to achieve. Dr. Erik Digman Wiklund
- ·4 t sittenWill there be a stock exchange announcement in two hours...? 🧐
- ·8 t sittenESGCT 27.-30. October - what do we actually know about the Circio abstracts? Facts Circio has three abstracts at ESGCT in Hamburg: - One oral presentation - Two posters The oral is titled "circVec: A DNA Vector Platform Harnessing Intracellular Circular RNA Biogenesis for Next-Generation T Cell Therapies" and will be held Wednesday 28. October at 10:00 in the session on non-viral vectors / nanotechnology and RNA therapeutics. The two posters: - P0089: circVec Reduces AAV Vector Dose Through Durable and Potent Circular RNA Expression - P0604: AAV-circVec Enhances Cardiac Expression While Minimizing Dose and Cellular Stress Full abstract texts will be released according to Circio on 27. October. The next R&D update is according to the Q2 call announced for the second half of November. My thoughts The poster titles are very similar to what we saw at ASGCT in May. I therefore expect updated AAV data (dose, expression, and cellular stress), not a completely new track. The oral is the more exciting one. The title points towards T cell therapy, but says nothing concrete about in vivo, LNP or CAR. It could just as well be in vitro data in human T cells as early in vivo results. Circio has itself guided in vivo T cell delivery, and CAR expression and durability in human T cells, as milestones over the next 6-12 months. Therefore I do not take for granted that the heaviest data will come already now. What I will look for - Is the expression shown in actual T cells (CD3/CD4/CD8), or just as total signal in spleen? - Is it CAR, or just reporter gene? - How long does it last, and what happens when the cells divide? - Is it compared against a strong control, or just own mVec? In short: Interesting program, but I am keeping my expectations in check until the abstracts are actually out.
- ·8 t sittenWould think that HOLD is the thing right now. And hence low turnover and few shares moving between hands among others. Only the daytraders tricking some bucks between themselves those who do not hold💥
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 666 | - | - | ||
| 1 | - | - | ||
| 306 | - | - | ||
| 5 000 | - | - | ||
| 683 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
42 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenJust a small refresher while we wait for news! The way forward We can look forward to several important R&D milestones in the second half of 2026 and the first half of 2027. These include the establishment of circVec generation 5 - an even more powerful circVec design that has shown the potential to provide 200 times or more gene expression compared to conventional AAV - the first in vivo data from AAV-circVec gene therapy in a relevant disease model, as well as in vivo results from the collaboration with the major pharmaceutical company. These results will be crucial when we define our R&D priorities and select a lead therapeutic candidate to be advanced towards clinical trials. To ensure access to key translational expertise in this central phase of Circio's development, the board has been strengthened through the appointment of Dr. Dinah Sah and by Dr. Robert Burns transitioning from deputy board member to regular board member. Dr. Sah has extensive experience in early drug development within RNA therapeutics and AAV gene therapy, and boasts a very strong track record. In her roles at Voyager Therapeutics and Alnylam Pharmaceuticals, she has led several programs from early research through to clinical development. Candidate selection, dosing, and the design of the preclinical documentation package are areas where gene therapy programs often win or lose. It is precisely in these areas that her experience is particularly relevant. With the expanded board, we are now developing both the corporate strategy and the R&D strategy for the next three to five years. Circio's ambition for the coming period is clear: We will continue to build on and consolidate our leading position in circular RNA technology. We will do this based on a therapeutic candidate that can establish clinical proof of concept, while translating strong scientific results into revenue-generating partnerships. The strict resource management and efficient R&D model that we have developed through four years of limited resources will be continued. What changes are the pace and scope of what we can now attempt to achieve. Dr. Erik Digman Wiklund
- ·4 t sittenWill there be a stock exchange announcement in two hours...? 🧐
- ·8 t sittenESGCT 27.-30. October - what do we actually know about the Circio abstracts? Facts Circio has three abstracts at ESGCT in Hamburg: - One oral presentation - Two posters The oral is titled "circVec: A DNA Vector Platform Harnessing Intracellular Circular RNA Biogenesis for Next-Generation T Cell Therapies" and will be held Wednesday 28. October at 10:00 in the session on non-viral vectors / nanotechnology and RNA therapeutics. The two posters: - P0089: circVec Reduces AAV Vector Dose Through Durable and Potent Circular RNA Expression - P0604: AAV-circVec Enhances Cardiac Expression While Minimizing Dose and Cellular Stress Full abstract texts will be released according to Circio on 27. October. The next R&D update is according to the Q2 call announced for the second half of November. My thoughts The poster titles are very similar to what we saw at ASGCT in May. I therefore expect updated AAV data (dose, expression, and cellular stress), not a completely new track. The oral is the more exciting one. The title points towards T cell therapy, but says nothing concrete about in vivo, LNP or CAR. It could just as well be in vitro data in human T cells as early in vivo results. Circio has itself guided in vivo T cell delivery, and CAR expression and durability in human T cells, as milestones over the next 6-12 months. Therefore I do not take for granted that the heaviest data will come already now. What I will look for - Is the expression shown in actual T cells (CD3/CD4/CD8), or just as total signal in spleen? - Is it CAR, or just reporter gene? - How long does it last, and what happens when the cells divide? - Is it compared against a strong control, or just own mVec? In short: Interesting program, but I am keeping my expectations in check until the abstracts are actually out.
- ·8 t sittenWould think that HOLD is the thing right now. And hence low turnover and few shares moving between hands among others. Only the daytraders tricking some bucks between themselves those who do not hold💥
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 666 | - | - | ||
| 1 | - | - | ||
| 306 | - | - | ||
| 5 000 | - | - | ||
| 683 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt